Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15416743 | 0.84 | CHRNB2 (0.34) | CHRNB2CHRNA4 | |
| SCHEMBL15427704 | 0.84 | CHRNB2 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL4568233 | 0.75 | KDM1A (0.43) | MEN1APAF1ALDH1A1POLBMAPT | |
| SCHEMBL4568235 | 0.75 | KDM1A (0.41) | MEN1APAF1ALDH1A1POLBMAPT | |
| SCHEMBL14364780 | 0.75 | CHRNB2 (0.36) | CHRNB2CHRNA4 | |
| SCHEMBL14003850 | 0.75 | CHRNB2 (0.36) | CHRNB2CHRNA4 | |
| SCHEMBL16905117 | 0.73 | AHR (0.32) | MEN1MAPTKMT2A | |
| SCHEMBL16905150 | 0.73 | PTK2 (0.41) | MEN1KMT2ACHRNB2CHRNA4 | |
| SCHEMBL18840501 | 0.73 | POLB (0.32) | MEN1POLBMAPTKMT2AL3MBTL1 | |
| SCHEMBL23985917 | 0.69 | CHRNB2 (0.31) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014008982-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150263297-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | MEN1 989/4885APAF1 3053/4885ALDH1A1 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.